UNASSIGNED: Extramedullary solitary plasmacytoma (EMP) is a rare type of @entity5 . This paper presents a retrospective review of the experience with EMP at the Krakow Oncology Center. Records of 17 @entity1 with @entity135 , treated with definitive radiotherapy between 1976 and 2009, were analyzed. The total @entity5 dose ranged from 45 to 70   Gy (median 56   Gy). In four @entity1 with partial response after radiotherapy, adjuvant melphalan-based chemotherapy was applied. The median follow-up period was 8.6   years. The treatment was well tolerated. The estimated 10-year overall survival, disease-free survival, and @entity1582 -free survival were 68.4%, 49.3%, and 55%, respectively. The 10-year local control rate was 90.9%. No in-field local recurrence was observed. During the follow-up, progression into @entity1582 was observed in five @entity1 , with a mean time to conversion of 24   months. The only factor adversely affecting overall survival on univariate analysis was the age >56   years, whereas a complete @entity5 regression after radiotherapy was associated with a significant improvement in both disease-free survival and @entity1582 -free survival. Despite the high effectiveness of local radiotherapy, there is still a significant treatment failure risk due to the EMP conversion into generalized disease. An attempt to identify prognostic factors may facilitate selection of @entity1 with a high risk of progression to @entity1582 . Copyright    2015 John Wiley _ Sons, Ltd.

Effect of definitive radiotherapy on the long-term outcome in XXXX with solitary extramedullary plasmacytoma.

@entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy', 'tumour'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck EMP'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma']
@entity1 :: (9606,Species) :: ['patients']
